Derisk investments through our unmatched pipeline and market vision. See the whole oncology field, beyond fragmented pitch decks, to lead your strategic investments or company creation with confidence.
Comprehensive Landscape Analysis
Expand the scope of your due diligence to the full cancer therapeutics universe
Evaluate 3,400+ oncology companies and 7,700+ assets across 35 metrics for technical success
Assess biotech acquisition/licensing potential across each pharmaceutical company
Proactively detect underrepresented targets or mechanisms that align with your thesis
Uncover companies with asymmetric upside and clear paths to liquidity events
Interrogate Platform Differentiation
Discern impactful science from futile hand-waving
Understand how 3,400+ companies each fit into the cancer therapeutics ecosystem
Contextualize isolated company materials across the entire sector
Pinpoint proprietary approaches that'll drive meaningful commercial outcomes
Generate outsized returns by avoiding me-too science and overly crowded markets
Align Your Incentives with Pharma & Patients
Tap into the clinical benchmarks and patient populations that matter
Extract the safety/efficacy metrics needed to turn your portfolio into industry standouts
Monitor the evolving patient landscape to detect expanding unmet need populations
Aggregate insights for all stakeholders across the clinical and commercial landscapes
Leverage the right data and back companies that are positioned to win
